Buy

Drew Craighead

Stock Overview• NYSE Ticker: COO

• PEG ratio: 1.70 Industry Average: 1.20

• Return on Equity: 11.9

• Beta: .1

• Semi-Annual Dividend: .03

• Growth slightly outpaced the industry at 4.3 %

Company Overview• The Cooper Companies, Inc. is a global medical

device company. The Company operates through two business units, CooperVision, Inc. and CooperSurgical, Inc. CooperVision is a global manufacturer providing products for contact lens wearers. CooperSurgical focuses on supplying women's health clinicians with products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has approximately 9,000 employees with products sold in over 100 countries.

Cooper Vision• CooperVision (CVI) has a long history of correcting

vision problems like astigmatism, presbyopia, and more.The company offers innovative contact lens solutions with focused support for eye care practitioners. This brings a refreshing perspective that creates real advantages for both eye doctors and contact lens wearers.

• In fiscal year 2011, CooperVision celebrated a milestone in achieving over $1 billion in global sales.

• Products: a wide variety of spherical, toric and multifocal contact lenses with monthly, two-week and daily disposable replacement schedules.

Cooper Vision

Coopersurgical• CooperSurgical (CSI) is the leading company dedicated to

providing medical devices and procedure-based solutions to the women’s healthcare segment regardless of clinical setting. Since its inception in 1990, CooperSurgical has steadily grown its market presence and distribution system by developing and purchasing products, and acquiring companies that complement its business focus. The company now has an established customer base serving well over 65% of women’s healthcare providers with sales in excess of $250 million.

• Products: From simple disposables to sophisticated instruments and equipment.

Competition

Cooper ManagementCEO-Robert S. Weiss

• Mr. Weiss has served as President since March 2008 and as Chief Executive Officer since November 2007. He also served as President of CooperVision, our contact lens subsidiary, from March 2007 to February 2008. He previously served as Chief Operating Officer from January 2005 to October 2007 and as Executive Vice President from October 1995 to October 2007. He served as Chief Financial Officer from September 1989 to January 2005. He served as Treasurer from 1989 to March 2002. Since joining us in 1977, he has held a number of finance positions both with us and Cooper Laboratories, Inc.

Problems• Cooper missed Q4 earnings, posting an earnings

of 1.95 rather than expectations of 2.03. This was a result of acquisition-related costs, offsetting the medical device maker’s higher revenue.

• Social sentiment is bearish.

• The Stock fell 6 % Friday as a result of their Q4 report released 12/5.

• They lowered their profit forecast

Conclusion• In conclusion, I find Cooper to

be an innovative leader within the medical device industry. Unlike Johnson & Johnson or Aetna , Cooper Companies have remained smaller allowing us the potential to buy a smaller innovative company in the healthcare industry which is booming as the result of new regulations. Although I believe Cooper has recently faced many challenges I believe they will begin to outperform competitors within the next two years.